Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Shares Outstanding (Weighted Average) (2018 - 2025)

BioNexus Gene Lab's Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $17.8 million for Q3 2024.

  • For Q3 2024, Shares Outstanding (Weighted Average) rose 5.93% year-over-year to $17.8 million; the TTM value through Sep 2024 reached $17.8 million, up 5.93%, while the annual FY2023 figure was $15.9 million, 10.17% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2024 was $17.8 million at BioNexus Gene Lab, up from $17.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $173.0 million in Q2 2022 and bottomed at $14.4 million in Q4 2022.
  • The 5-year median for Shares Outstanding (Weighted Average) is $102.7 million (2020), against an average of $83.4 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) soared 66.67% in 2021 before it crashed 91.63% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $102.9 million in 2020, then surged by 66.36% to $171.2 million in 2021, then plummeted by 91.58% to $14.4 million in 2022, then grew by 10.17% to $15.9 million in 2023, then rose by 11.92% to $17.8 million in 2024.
  • Per Business Quant, the three most recent readings for BGLC's Shares Outstanding (Weighted Average) are $17.8 million (Q3 2024), $17.7 million (Q2 2024), and $17.7 million (Q1 2024).